The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024

Al Nasar Ahmed Sehgal, Peter A Tauber, Robert B Stieger, Bernhard Kratzer, Winfried F Pickl*

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Review article

Abstract

Interleukin(IL)-2 was originally characterized as an important T-cellular growth factor but later on, turned out to be a pivotal homeostatic factor for the establishment and maintenance of both natural(n)Treg and peripheral(p)Treg. In this review, it was aimed to connect the peculiar structural and functional aspects of IL-2 to the innovative advancements in tailoring its multifaceted functional behavior for targeting various IL-2 receptor types. The article includes detailed descriptions of modified versions of IL-2, obtained by either mutating or fusing IL-2 to heterologous molecules or by forming IL-2/(monoclonal) antibody complexes (IL-2C), and discusses their functional implications for addressing such heterologous pathological conditions in cancer, autoimmunity, and allergy. Additionally, this review sheds light on the underexplored contribution of autoantibodies to the endogenous regulation of IL-2 within the realms of both health and disease. The ongoing efforts to fine-tune IL-2 responses through antibody-dependent targeting or molecular engineering offer considerable translational potential for the future utility of this important cytokine.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalInternational Archives of Allergy and Immunology
Early online date12 Dec 2023
DOIs
Publication statusE-pub ahead of print - 12 Dec 2023

Keywords

  • Allergy
  • Autoimmunity
  • Cancer
  • IL-2C
  • IL-2R
  • Interleukin-2
  • Muteins
  • T cell growth factor
  • T regulatory cells
  • Treg

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024'. Together they form a unique fingerprint.

Cite this